IBRANCE® (palbociclib) is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, IBRANCE works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast cancer.
IBRANCE is taken with hormonal therapy and is used to treat hormone receptor positive, HER2- metastatic breast cancer. In combination with letrozole (sometimes called Femara®), IBRANCE is for postmenopausal women as their first hormonal based therapy. In combination with fulvestrant (known as Faslodex®), IBRANCE is for women who have previously received…
